CoChat

Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association

Rangaswami, Janani, Bhalla, Vivek, de Boer, Ian H., Staruschenko, Alexander, Sharp, Johanna A., Singh, Radhika Rajgopal, Lo, Kevin Bryan, Tuttle, Katherine, Vaduganathan, Muthiah, Ventura, Hector, McCullough, Peter A., On behalf of the American Heart Association Council on the Kidney in Cardiovascular Disease; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; and Council on Lifestyle and Cardiometabolic Health · 2020 · Circulation

The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.

Abstract

Chronic kidney disease (CKD) with type 2 diabetes (T2D) is a major public health problem, resulting in significant cardiovascular and kidney adverse outcomes worldwide. Despite the widespread use of standard-of-care therapies for CKD with T2D over the past few decades, rates of progression to end-stage kidney disease remain high with no beneficial impact on its accompanying burden of cardiovascular disease. The advent of the newer classes of antihyperglycemic agents, including SGLT2 (sodium glucose cotransporter 2) inhibitors and GLP-1 (glucagon-like peptide-1) receptor agonists, has changed the landscape of therapeutic options for patients with CKD with T2D, with demonstration of significant reductions in cardiovascular adverse events and progression to end-stage kidney disease. Several potential mechanisms exist through which these beneficial effects are achieved in both drug classes, which may be independent of their antihyperglycemic effects. This scientific statement summarizes the current literature on the cardiorenal protective effects with SGLT2 inhibitors and GLP-1 receptor agonists in patients with CKD and T2D. It reviews potential mechanistic pathways that may drive these benefits and summarizes the literature on adverse effects in patients with CKD and T2D at risk for or with established cardiovascular disease. Last, it provides practical guidance on a proposed collaborative care model bridging cardiologists, nephrologists, endocrinologists, and primary care physicians to facilitate the prompt and appropriate integration of these therapeutic classes in the management of patients with T2D and CKD.

Overview

Integrity signals

Registry

Crossref · 10.1161/cir.0000000000000920

Cites

81 of 81 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 81 references

Research works printed but not linked: 6

  1. United States Renal Data System 2017 USRDS Annual Data Report.: Epidemiology of Kidney Disease in the United States. Bethesda, MD: National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2017.
  2. Bakris, GL, Oshima, M, Mahaffey, KW, Charytan, DM, Levin, A, Pollock, C, Wheeler, DC, Zhang, H, Greene, T, Capuano, G, et al. Canagliflozin (CANA) slows decline in kidney function in people with baseline eGFR < 30 cc/min/1.73m2. American Society of Nephrology Kidney Week 2019. TH-P01202.
  3. Wanner, C ZB, George, JT, Mattheus, M, von Eynatten, M, Inzucchi, SE, Hauske, SJ,. Empaglifflozin and cardiorenal outcomes in patients with non proteinuric kidney disease in the EMPAREG-OUTCOME trial. European Association for the Study of Diabetes. 2019.
  4. K DIGO. Guideline on the management of diabetic in chronic kidney disease (public commentary document). https://kdigo.org/wp-content/uploads/2018/03/KDIGO-Diabetes-Management-in-CKD_Public-Review.pdf. Accessed February 15 2020.
  5. Charytan, DM, Mahaffey, K, Jardine, M, Agarwal, R, Bull, S, Chu, P, de-Zeeuw, D, Greene, T, Heerspink, HJL, Neal, B, et al. Renoprotective effects of canagliflozin in CREDENCE may be independent of its glucose lowering mechanisms. American Society of Nephrology Kidney Week 2019. FR-P0223.
  6. Tuttle, KR, Lakshmanan, M Gross, JL Rayner, B Busch, RS Woodward, B Zimmermann, AG Botros, FT. Dulaglutide treatment is associated with less eGFR decline and greater reduction in albuminuria in type 2 diabetes and CKD stages 3-4 (AWARD-7). American Society of Nephrology Kidney Week 2019. SA-OR081.

Cited by

See all 192

Metadata

Authors
Rangaswami, J., Bhalla, V., de Boer, I. H., Staruschenko, A., Sharp, J. A., Singh, R. R., Lo, K. B., Tuttle, K., Vaduganathan, M., Ventura, H., McCullough, P. A., & On behalf of the American Heart Association Council on the Kidney in Cardiovascular Disease; Council on Arteriosclerosis, T. A. V. B. C. O. C. A. S. N. C. O. C. C. A. C. O. L. A. C. H.
Venue
Circulation
Published
2020-10-27
Volume
142
Issue
17
Pages
e265-e286
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W3088226103
Cited by
192
References
81
Citations by year
2026: 25 · 2025: 35 · 2024: 24 · 2023: 37 · 2022: 33 · 2021: 31 · 2020: 6
FWCI
4.09
Type
journal article
Language
en
Open access
closed
Locations
  • Circulation (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
Keywords
chronic kidney disease, type 2 diabetes, SGLT2 inhibitors, GLP-1 receptor agonists, cardiorenal protection, cardiovascular outcomes, end-stage kidney disease progression, antidiabetic drugs, drug mechanisms, adverse effects, collaborative care
MeSH terms
American Heart Association, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, United States, Renal Insufficiency, Chronic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association. https://app.cochat.ai/papers/10.1161/cir.0000000000000920
The paper
Rangaswami, J., Bhalla, V., de Boer, I. H., Staruschenko, A., Sharp, J. A., Singh, R. R., Lo, K. B., Tuttle, K., Vaduganathan, M., Ventura, H., McCullough, P. A., & On behalf of the American Heart Association Council on the Kidney in Cardiovascular Disease; Council on Arteriosclerosis, T. A. V. B. C. O. C. A. S. N. C. O. C. C. A. C. O. L. A. C. H. (2020). Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association. Circulation. https://doi.org/10.1161/cir.0000000000000920

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.